Neuraminidase inhibitor resistance in influenza viruses

Journal of Medical Virology

Volumn 79, Issue 10, 2007, Pages 1577-1586

  Reece, Phillip Andrew ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE   (Australia)

Author keywords

Avian; H5N1; Oseltamivir; Pandemic; Peramivir; Zanamivir

Indexed keywords

AMANTADINE; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ARTICLE; CATALYSIS; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOCOMPETENCE; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NONHUMAN; VIRULENCE; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VIRUS VIABILITY;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CHILD; CLINICAL TRIALS; CYCLOPENTANES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GUANIDINES; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SEASONS; SENTINEL SURVEILLANCE; VIRAL PROTEINS; VIRULENCE; ZANAMIVIR;

AVES; ORTHOMYXOVIRIDAE;

EID: 34548223154     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20951     Document Type: Article

References (132)

1. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G. 2002. Characterization of 2 influenza A(H3N2) Clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 186:1074-1080.
2. Abed Y, Goyette N, Boivin G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 9:577-581.
3. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Horn LL, Laver GW, Montgomery JA. 2000. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482-3486.
4. Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R. 1999. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265:286-295.
5. Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ, Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, De Groot R, Osterhaus AD. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 44:78-87.
6. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43:1555-1561.
7. Baz M, Abed Y, Boivin G. 2007. Characterization of drug-resistant recombinant influenza A/H1N1viruses selected in vitro with peramivir and zanamivir. Antiviral Res 74:159-162.
8. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY. 2005. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Consultation on human influenza A/H5Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-1385.
9. Blick T. 1998. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246:95-103.
10. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. 1999. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43:1616-1620.
11. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, Tai L, Roberts N. 2003. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir Res 54:79-88.
12. Cass LMR, Brown J, Pickford M, Fayinka S, Newman SP, Johansson SJ, Bye A. 1999. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 36:21-31.
13. Cheam AL, Barr IG, Hampson AW, Mosse J, Hurt AC. 2004. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 63:177-181.
14. Cheer S, Wagstaff A. 2002. Zanamivir - an update of its use in influenza. Drugs 62:71-106.
15. Chokephaibulkit K, Uiprasertkul M, Puthavathana P, Chearskul P, Auewarakul P, Dowell SF, Vanprapar N. 2005. A child with avian influenza A (H5N1) infection. Pediatr Infect Dis J 24:162-166.
16. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A, Dowell SF. 2005. Human disease from influenza A (H5N1) Thailand, 2004. Emerg Infect Dis 11:201-209.
17. Chutinimitkul S, Suwannakarn K, Chieochansin T, Mai le Q, Damrongwatanapokin S, Chaisingh A, Amonsin A, Landt O, Songserm T, Theamboonlers A, Poovorawan Y. 2005. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352:686-691.
18. Chutinimitkul S, Bhattarakosol P, Srisuratanon S, Eiamudomkan A, Kongsomboon K, Damrongwatanapokin S, Chaisingh A, Suwannakarn K, Chieochansin T, Theamboonlers A, Poovorawan Y. 2006. H5N1 influenza A virus and infected human plasma. Emerg Infect Dis 12:1042-1043.
19. Chutinimitkul S, Suwannakarn K, Chieochansin T, Mai le Q, Damrongwatanapokin S, Chaisingh A, Amonsin A, Landt O, Songserm T, Theamboonlers A, Poovorawan Y. 2007. H5N1 oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J Virol Methods 139:44-49.
20. Colman P. 2002. Neuraminidase inhibitors as antivirals. Vaccine 20: S55-S58.
21. Colman P. 2005. Zanamivir: An influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther 3:191-199.
22. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667-2672.
23. de Jong MD, Hien TT. 2006. Avian influenza A (H5N1). J Clin Virol 35: 2-13.
24. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203-1207.
25. Dwyer DE, Smith DW, Catton MG, Barr IG. 2006. Laboratory diagnosis of human seasonal and pandemic influenza virus infection. Med J Aust 185:S48-S53.
26. Ferraris O. 2005. Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antivir Res 68:43-48.
27. Ferraris O, Kessler N, Valette M, Lina B. 2006. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005. Vaccine 24:6656-6659.
28. Fleming D. 2003. Zanamivir in the treatment of influenza. Expert Opin Pharmacother 4:799-805.
29. Govorkova EA, Leneva LA, Goloubeva OG, Bush K, Webster RG. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45:2723-2732.
30. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E. 2005. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79:2191-2198. Erratum in: J Virol 2006; 80(12): 6195.
31. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51:1414-1424.
32. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 70:1818-1827.
33. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998a. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257-1262.
34. Gubareva LV, McCullers JA, Bethell RC, Webster RG. 1998b. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 178:1592-1596.
35. Gubareva LV, Kaiser L, Hayden FG. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
36. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183: 523-531.
37. Gubareva LV, Webster RG, Hayden FG. 2002. Detection of influenza virus resistance to neuraminidase inhibitors. Antiviral Res 53:47-61.
38. Gubareva LV. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 103:199-203.
39. Gupta RK, Nguyen-Van-Tam JS. 2006. Oseltamivir resistance in influenza A (H5N1) infection. N Engl J Med 354:1423-1424; author reply: 1423-1424. Comment on: N Engl J Med 2005; 353(25): 2667-2672.
40. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 48:4473-4475.
41. Harrod ME, Emery S, Dwyer DE. 2006. Antivirals in the management of an influenza pandemic. Med J Aust 185:S58-S61.
42. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
43. Hayden FG. 1997. Prevention and treatment of influenza in immunocompromised patients. Am J Med 102:55-60; discussion: 75-76.
44. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 282:1240-1246.
45. Hayden FG. 2005a. Antivirals and Immunotherapies in pandemic influenza, IOM Briefing, April 4, 2005. http://www.iom.edu/Object.File/Master/26/446/ Group%204%20Briefmg_Hayden.pdfatpage 26.
46. Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M. 2005b. Neuraminidase inhibitor susceptibility network position statement: Antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 10:873-877. Review. Erratum 2006, in: Antivir Ther 11(1):130.
47. Hayden FG. 2006a. Abstract of presentation in a session entitled "Antivirals: Effectiveness, Drug Resistance, and New Agents" at the 46th ICAAC, September 2006, San Francisco.
48. Hayden FG. 2006b. Antivirals for influenza: Historical perspectives and lessons learned. A mini Review. Antivir Res 71:372-437.
49. Hayden FG, Pavia AT. 2006. Antiviral management of seasonal and pandemic influenza. J Infect Dis 194:S119-S126.
50. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484.
51. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O. 2000. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age. Pediatr Infect Dis J 19:410-417.
52. Herlocher L. 2001. Influenza resistance to zanamivir generated in ferrets. Int Congr Ser 1219:863-877.
53. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antivir Res 54: 99-111.
54. Herlocher ML, Truscon R, Fenton R, Klimov A, Elias S, Ohmit SE, Monto AS. 2003. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. J Inf Dis 188:1355-1361.
55. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets. J Infect Dis 190:1627-1630.
56. Hurt AC, Barr IG, Hartel G, Hampson AW. 2004. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antivir Res 62:37-45.
57. Hurt AC, Ho HT, Barr I. 2006a. Resistance to anti-influenza drugs: Adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 4:795-805.
58. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, McKimm-Breschkin JL. 2006b. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 50:1872-1874.
59. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. 2006c. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antivir Res 73:228-231.
60. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. 2006. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir Res 70:121-131.
61. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 193:760-764. Comment in: J Infect Dis 2006; 193(6):751-753.
62. Ives J, Carr J, Roberts NA, Tai CY, Mendel DB, Kelly L, Lambkin R, Oxford J. 2000. An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J Clinical Virol 18:251.
63. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55:307-317.
64. Iyer GR, Liao S, Massarella J. 2002. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. AAPS PharmSci 4:E22.
65. Jackson D, Barclay W, Zurcher T. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55:162-169.
66. Jackson HC, Roberts N, Wang ZM, Belshe R. 2000. Management of influenza: Use of new antivirals and resistance in perspective. Clin Drug Invest 20:447-454.
67. Kim CU, Lew W, William MA, Liu H, Zhang I, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, W. Laver G, Stevens RC. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent antiinfluenza activity. J Am Chem Soc 119:681-690.
68. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 364:759-765.
69. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M, Feldmann F, Alimonti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-323.
70. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437:1108-1109.
71. Luo M. 2006. Antiviral drugs fit for a purpose. Nature 443:37-38.
72. Lye DC, Nguyen DH, Giriputro S, Anekthananon T, Eraksoy H, Tambyah PA. 2006. Practical management of avian influenza in humans. Singapore Med J 47:471-475.
73. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY, Tucker SP. 2004. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 48:4542-4549.
74. Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP. 2005. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 48: 2964-2971.
75. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM. 2005. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79:11788-11800.
76. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. 1996. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225:240-242.
77. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN. 1998. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 72: 2456-2462.
78. McKimm-Breschkin JL. 2000. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res 47:1-17.
79. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, Zambon M. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47: 2264-2272.
80. McKimm-Breschkin JL. 2005. Management of influenza virus infections with neuraminidase inhibitors: Detection, incidence, and implications of drug resistance. Treat Respir Med 4:107-116.
81. Mendel DB, Sidwell RW. 1998. Influenza virus resistance to neuraminidase inhibitors. Drug Resist Update 1:184-189.
82. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515-4520.
83. Molla A, Kati W, Carrick R, Steffy K, Shi Y, Montgomery D, Gusick N, Stoll VS, Stewart KD, Ng TI, Maring C, Kempf DJ, Kohlbrenner W. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 76:5380-5386.
84. Monto A. 2006. Vaccines and antiviral drugs in pandemic preparedness. Emer Inf Dis 12:55-60.
85. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006b. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50:2395-2402.
86. Moscona A. 2005a. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med 353:2633-2636.
87. Moscona A. 2005b. Neuraminidase inhibitors for influenza. N Engl J Med 353:1363-1373.
88. Nedyalkova MS, Hayden FG, Webster RG, Gubareva LV. 2002. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA. J Infect Dis 185:591-598.
89. Nicholson KG, Wood JM, Zambon M. 2003. Influenza. Lancet 362: 1733-1745.
90. NIH. 2007. Clinical research studies. A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects. http:// clinicalstudies.info.nih.gov/detail/B_2006-I-0105.html.
91. Oxford J, Balasingam S, Lambkin R. 2004. A new millennium conundrum: How to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J Antimicrob Chemother 53:133-136.
92. Oxford J. 2005. Oseltamivir in the management of influenza. Expert Opin Pharmacother 6:2493-2500.
93. Peng AW, Hussey EK, Moore KH. 2000a. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: Effects of formulation and route of administration. J Clin Pharmacol 40:242-249.
94. Peng AW, Milleri S, Stein DS. 2000b. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother 44:1974-1976.
95. Regoes RR, Bonhoeffer S. 2006. Emergence of drug-resistant influenza virus: Population dynamical considerations. Science 312:389-391.
96. Relenza label approved by the FDA on 29 March 2006. http://www.fda.gov/ cder/foi/label/2006/021036s0081bl.pdf.
97. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. 2001. Pathogenesis of Influenza A (H5N1) Virus Infection in a Primate Model. J Virol 75:6687-6691.
98. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49.
99. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD. 2007. WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7:21-31.
100. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
101. Sidwell R. 2001. A consideration of animal models used for study of influenza virus inhibitors. Int Congr Ser 1219:835-838.
102. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. 2001a. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45:743-748.
103. Smee DF, Sidwell RW, Morrison AC, Bailey KW, Baum EZ, Ly L, Wagaman PC. 2001b. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res 52:251-259.
104. Smith BJ, McKimm-Breshkin JL, McDonald M, Fernley RT, Varghese JN, Colman PM. 2002. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45:2207-2212.
105. Tamiflu label approved by the FDA on 13 November, 2006. http://www.fda.gov/cder/foi/label/2006/021087s0331bl.pdf.
106. The Royal Society. 2006. Pandemic influenza: Science to policy. Policy document 36/06. ISBN-13: 978 0 85403 635 6. ISBN-10: 0 85403 635 0. Report can be found at www.royalsoc.ac.uk and www.acmedsci.ac.uk.
107. Tisdale M. 2000. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors. Rev Med Virol 10:45-55.
108. Tsang KW, Eng P, Liam CK, Shim YS, Lam WK. 2005. H5N1 Influenza Pandemic: Contingency Plans. Lancet 366:533-534.
109. Uiprasertkul M, Puthavathana P, Sangsiriwut K, Pooruk P, Srisook K, Peiris M, Nicholls JM, Chokephaibulkit K, Vanprapar N, Auewarakul P. 2005. Influenza A (H5N1) replication sites in humans. Emer Inf Dis 11:1036-1041.
110. US Department of Health and Human Services. 2007. HHS Pursues Advance Development of New Influenza Antiviral Drug. http://www.hhs.gov/news/press/ 2007pres/20070104.html.
111. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
112. Varghese JN, Epa VC, Colman PM. 1995. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 4:1081-1087.
113. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM. 1998. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-746.
114. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW., et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
115. Wang MZ, Tai CY, Mendel DB. 2002. Mechanism by which mutations at His274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 46:3809-3816.
116. Ward P, Small I, Smith J, Suter P, Dutkowski R. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55:i5-i21.
117. Wei DQ, Du QS, Sun H, Chou KC. 2006. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem Biophys Res Commun 344: 1048-1055.
118. Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41:742-750.
119. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. 2001. Oral oseltamivir treatment of influenza in children. J Pediatr Infect Dis 20:127-133.
120. Whitley RJ, Monto AS. 2006. Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 194:S133-S138.
121. WHO. 2005a. WHO intercountry-consultation Influenza A/H5N1 in humans in Asia. http://www.who.int/csr/resources/publications/influenza/ WHO_CDS_CSR_GIP_2005_7_04.pdf.
122. WHO. 2005b. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 Avian Influenza Viruses in Asia. Emerg Infect Dis 11:1515-1521.
123. WHO. 2007a. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 82:141-152.
124. WHO. 2007b. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines, March 2007. Wkly Epidemiol Rec 82:161-168.
125. WHO. 2007c. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO, 16 May 2007. http://www.who.int/csr/disease/ avian_influenza/country/cases_table_2007_05_16/en/index.html.
126. WHO. 2007d. Avian influenza - situation in Egypt - update, 18 January 2007. http://www.who.int/csr/don/2007_01_18/en/index.html.
127. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. 2005a. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-4084.
128. Yen HL, Monto AS, Webster RG, Govorkova EA. 2005b. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice. J Infect Dis 192:665-672.
129. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80:8787-8795.
130. Yuen KY, Wong SS. 2005. Human infection by avian influenza A H5 N1. Hong Kong Med J 11:189-199.
131. Zambon M. 2001. The pathogenesis of influenza in humans. Rev Med Virol 11:227-241.
132. Zurcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL. 2006. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise flu fitness and are not stably maintained in vitro. J Antimicrob Chemother 58:723-732.